Prof. Fernando Calamante
Prof. Fernando Calamante studied physics in Argentina and obtained his PhD in MRI from University College London in 2000. Fernando relocated to the Florey Institute of Neuroscience and Mental Health and the University of Melbourne in 2005. His main areas of research are Perfusion MRI and Diffusion MRI, and their applications to neurology and neuroscience.
He has gained international recognition for his work on Perfusion MRI in particular which is highly cited and at the forefront of the field. His Diffusion MRI methods and software tool (MRtrix) are also widely used worldwide. Fernando has been elected to several leadership positions within the International Society for Magnetic Resonance in Medicine (including as 2021-2022 President).
He joined the University of Sydney in April 2018 and is currently the Director of Sydney Imaging Core Research Facility and Professor at the School of Biomedical Engineering.
Miguel Palacios is a medical physicist at the AUMC. He has been involved with the clinical implementation of the MRI-Linac at their centre, and in a variety of novel applications of their device, including single fraction lung stereotactic ablative radiation therapy (SABR), and treating ultracentral lung cancer with SABR. He has interests in motion management and adaptive radiation therapy and has been the co-author of several peer-reviewed articles on MR-guided radiotherapy.
Dr Alison Tree
Alison Tree was appointed as a consultant clinical oncologist at the Royal Marsden NHS Foundation Trust in 2014, specialising in urological malignancies. Her MD thesis was on stereotactic body radiotherapy (SBRT) techniques for prostate and oligometastatic cancer.
Her current research interests focus on technical radiotherapy developments in prostate cancer, aiming to make radiotherapy more effective and reduce side effects. Dr Tree leads the Prostate Group in the International MR Linac consortium. She is currently leading trials in MR-guided prostate radiotherapy (the PRISM trial), boosting dominant intra-prostatic lesions (the DELINEATE trial) and ablating oligoprogressing metastases in advanced prostate cancer (the TRAP trial). She will soon be starting the HERMES trial which is testing whether prostate cancer can be cured in just 2 fractions.
- Prostate and pelvic radiotherapy
- Penile cancer radiotherapy
- Palliative radiotherapy
- Stereotactic body radiotherapy
- Treatment of oligomestases